Bluebird bio Profit Margin

Bluebird bio (BLUE) currently reports a profit margin of -1.92% as of March 2025. That compares with -6.63% in the prior-year period — up 71.0% year over year. That is below the Healthcare sector average of 15.58%. Use the charts on this page to explore Bluebird bio's profit margin history and peer comparisons.

Bluebird bio's profit margin increased from -6.63% to -1.92% — a 71.0% year-over-year increase (period ending March 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Bluebird bio's profit margin of -1.92% is lower than the Healthcare sector average of 15.58%. That is roughly 1334.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Bluebird bio's current -1.92% should be judged against Healthcare norms (sector average: 15.58%) and against BLUE's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -1.92%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 15.58%. From there, open related valuation or income-statement pages for Bluebird bio, and consider following BLUE for alerts when major investors trade the stock.